Advertisement

Reactions Weekly

, Volume 1729, Issue 1, pp 23–23 | Cite as

Anti-inflammatories/antineoplastics

Various toxicities: 3 case reports
Case report
  • 57 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective study of 5 patients with refractory Behcet's uveitis (BU), who were treated with tocilizumab between December 2014 and March 2017 at the Istanbul university, 2 women and 1 man, aged 21-27 years, were described, who developed myalgia, severe fatigue, neutropenia, infusion reactions, increase in liver enzymes or increase in cholesterol levels during treatment with Interferon α 2a, interferon, infliximab or off-label tocilizumab for BU [not all routes, dosages and durations of treatments to reaction onsets stated; outcomes not stated].

Case 1: A 24-year-old woman presented with a six month history of BU and progressive visual loss, bilaterally. At the time of presentation, visual acuity was decreased. She had multiple retinal infiltrates in both eyes, 3+ cells in...

Reference

  1. Eser Ozturk H, et al. Tocilizumab for the Treatment of Behcet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocular Immunology and Inflammation 26: 1005-1014, No. 7, 3 Oct 2018. Available from: URL: http://doi.org/10.1080/09273948.2017.1355471 - TurkeyCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations